Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), PTC Therapeutics, Inc. (NASDAQ:PTCT), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

img-413-Unsplash-is-a-s

US drugmaker Pfizer Inc (NYSE:PFE) on Monday abandoned its pursuit to buy AstraZeneca PLC, saying it does not plan to make an offer for the British drugmaker following the rejection of its final proposal last week. Pfizer Inc. (NYSE:PFE) stock performance was -0.57% in last session and finished the day at $29.49. Traded volume was 18.93million shares in the last session and the average volume of the stock remained 30.91million shares. The beta of the stock remained 0.73. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Zacks upgraded shares of Gilead Sciences Inc (NASDAQ:GILD) from a neutral rating to an outperform rating in a report issued on Friday. They currently have $99.00 target price on the stock. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -2.36 percent to $80.94 Friday on volume of 13.60million shares. The intra-day range of the stock was $80.75 to $82.50. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $124.30billion.

PTC Therapeutics, Inc. (NASDAQ:PTCT) shares nearly doubled this past Friday after the company received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe for translarna, which is the branded name given to ataluren, the company’s lead investigational compound. PTC Therapeutics, Inc. (NASDAQ:PTCT)’s stock on May 23, 2014 reported a increase of 30.74% to the closing price of $20.03. Its fifty two weeks range is $13.03 -$34.65. The total market capitalization recorded $602.39billion. The overall volume in the last trading session was 10.20million shares. In its share capital, PTCP has 30.07million outstanding shares.

Inovio Pharmaceuticals Inc (NYSEMKT:INO), a drug development company working on treatments that modulate therapeutically important immune responses with the help of T-cells, recently acquired the worldwide rights (apart from China), to conduct pre-clinical studies to produce products for possible therapies to treat and manage Alzheimer’s Disease (AD) and Multiple Sclerosis (MS). On Friday, shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -9.09% to close the day at $2.00. Company return on investment (ROI) is -37.10% and its monthly performance is recorded as -23.08%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) quarterly revenue growth is -46.24%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone